VALSARTAN AND SACUBITRIL

DRUG6 trials

Conditions

Cardiovascular DiseasesHeart FailureHeart Failure With Reduced Ejection FractionHeart failureHeart failure with reduced ejection fractionNon-ischemic cardiomyopathyheart failure with moderately reduced ejection fraction (HFmrEF)

Phase 2

A multi-center, randomized, placebo- and active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure

CompletedCTIS2023-504678-39-00

Novartis Pharma AGHeart Failure

Start: 2024-03-13End: 2024-11-08Target: 424Updated: 2024-11-08

Phase 3

Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial

CompletedCTIS2022-502409-14-00

University Of Porto, University Of PortoHeart failure with reduced ejection fraction

Start: 2023-08-04End: 2025-07-31Target: 172Updated: 2025-05-27

BONFIRE - Beta-blockers discontinuation in patients presenting heart failure with recovered left ventricular ejection fraction

RecruitingCTIS2023-508798-94-00

Assistance Publique Hopitaux De ParisHeart failure

Start: 2025-02-11Target: 1300Updated: 2025-11-13

The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction.

RecruitingCTIS2024-518239-12-00

Krakowski Szpital Specjalistyczny Im. Sw. Jana Pawla IIheart failure with moderately reduced ejection fraction (HFmrEF)

Start: 2023-01-26Target: 666Updated: 2025-10-29

Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.

Not yet recruitingCTIS2025-521780-12-00

Andrea Di MarcoNon-ischemic cardiomyopathy

Target: 64Updated: 2025-12-05

Phase 4

Determination of Drug Levels for Pharmacotherapy of Heart Failure

Not yet recruitingNCT06035978

University Hospital OstravaCardiovascular Diseases, Heart Failure With Reduced Ejection Fraction

Start: 2024-03-31End: 2026-04-30Target: 100Updated: 2024-01-18

Related Papers

Rationale and design of Dapagliflozin vErsus SacubiTrIl-valsartaN therapY in Heart Failure with reduced ejection fraction (DESTINY-HF): a pragmatic randomised controlled trial protocol